MCM3 and breast cancer: Subsequently, MCM3 expression was evaluated in the second cohort consisting of 218 postmenopausal patients with high-risk, early-stage, ER+ breast cancers, who had received adjuvant tamoxifen mono-therapy (Supplementary Table 2).